Flash Finance

Senores Pharmaceuticals LimitedSENORESCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 11 quarters of data
Consolidated Standalone
₹1,318.40
MCap ₹6,072 Cr · P/E 326.6
Senores Pharmaceuticals Limited — Stock analysis & AI research Senores Pharmaceuticals Limited — Multibagger AI analysis Senores Pharmaceuticals Limited — Seasonality — best & worst months Senores Pharmaceuticals Limited — Technical indicators & charts Senores Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Senores Pharmaceuticals Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 📈 Bollinger Squeeze Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹27 Cr
Sales · Jun 2026
+36.2% YoY
₹-2 Cr
Operating Profit · Jun 2026
-100.9% YoY
-8.6%
OPM % · Jun 2026
-45.8% YoY
₹1 Cr
Net Profit · Jun 2026
-61.9% YoY
₹0.22
EPS · Jun 2026
-62.7% YoY

📝 Senores Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Senores Pharmaceuticals Limited reported revenue of ₹27 crore for the quarter ended June 2026 (Q1 FY27), up 36.2% from ₹20 crore in the same quarter last year, and down 26.7% sequentially over the March 2026 quarter.

Net profit fell 61.9% year-on-year to ₹1 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.22.

Operating profit stood at ₹-2 crore — an operating margin (OPM) of -8.6%, compared with -5.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Senores Pharmaceuticals Limited posted revenue of ₹121 crore, a growth of 213.1% over FY25, with a net profit of ₹20 crore (up 449.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹128 crore with a net profit of ₹19 crore.

Valuation snapshot

At the current price of ₹1,318.40, SENORES has a market capitalisation of ₹6,072 crore and a trailing P/E of about 326.6.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 5th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 45.82%, foreign institutional investors (FIIs) 6.01%, domestic institutional investors (DIIs) 10.84%, public shareholders 37.33% of Senores Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹6,072 Cr
Current Price ?
₹1,318.4
P/E ?
326.61above ind
Industry P/E ?
21.30
P/B ?
8.10
P/S ?
47.48
P/FCF ?
-97.93
Enterprise Value ?
₹6,157 Cr
EV/EBITDA ?
-1,179.45
PEG ?
2.08
Earnings Yield ?
-0.3%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹128 Cr
OPM ?
-4.1%
Profit after tax (TTM) ?
₹19 Cr
EPS (TTM) ?
₹4.04
ROCE ?
4.0%
ROE ?
2.5%
ROA ?
2.1%
Growth
Sales — latest qtr ?
₹27 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
36.2%
YoY qtr profit growth ?
-61.9%
Sales growth (3y) ?
105%
Sales growth (5y) ?
68%
Profit growth (3y) ?
157%
Profit growth (5y) ?
89%
Financial Health
Debt ?
₹85 Cr
Debt to Equity ?
0.11
Interest Coverage ?
-2.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
45.82%
Change in promoter holding ?
0.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.2%
Return 6 months ?
47.5%

🗓️ Quarterly results (11 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 91171010122035293727 +36.2% -26.7%
Operating Profit -12-1-1-2-3-12-1-3-2 -100.9% +33.0%
Other Income 252379811102210 +13.8% -57.0%
Interest 11113222222 +26.1% +17.5%
Depreciation 01111124444 +92.0% -12.6%
Profit Before Tax 060113484131 -61.3% -89.0%
Net Profit 0-3001236381 -61.9% -87.9%
EPS 0.07-1.090.090.090.320.390.591.401.981.840.22 -62.7% -88.0%
OPM % -5.9% 17.6% -10.4% -13.9% -25.2% -23.0% -5.9% 4.3% -3.2% -9.5% -8.6% -45.8% +9.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹39 Cr ₹121 Cr ₹128 Cr +213.1%
Operating Profit ₹-7 Cr ₹-4 Cr ₹-5 Cr +44.3%
OPM % -18.85% -3.35% -4.08% +82.2%
NPM % 9.57% 16.78% 14.54% +75.3%
Other Income ₹22 Cr ₹52 Cr ₹53 Cr +135.3%
Depreciation ₹3 Cr ₹13 Cr ₹15 Cr +331.3%
Interest ₹7 Cr ₹7 Cr ₹7 Cr +6.9%
EBIT ₹-10 Cr ₹-17 Cr ₹-20 Cr -67.2%
PBT ₹5 Cr ₹27 Cr ₹25 Cr +438.2%
Tax ₹1 Cr ₹7 Cr ₹7 Cr +538.1%
Net Profit ₹4 Cr ₹20 Cr ₹19 Cr +449.1%
EPS ₹0.89 ₹5.81 ₹5.44 +552.8%
Material Cost ₹14 Cr ₹55 Cr ₹63 Cr +279.0%
Employee Cost ₹9 Cr ₹39 Cr ₹42 Cr +313.9%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 10314646 +0.0%
Reserves 29138662704 +6.3%
Borrowings 6110110385 -17.5%
Other Liabilities 12172353 +130.4%
Total Liabilities 112286834888 +6.5%
Fixed Assets 82455102 +85.5%
CWIP 1118349 -73.5%
Investments 882104154 +48.1%
Other Assets 84162641623 -2.8%
Total Assets 112286834888 +6.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -43-19-20-27 -35.0%
Cash from Investing Activity -5-57-163-19 +88.3%
Cash from Financing Activity 4787533-3 -100.6%
Net Cash Flow -210349-49 -114.0%
Free Cash Flow -52-39-70-62 +11.4%
CFO/OP 2,412%30,117%260%118% -54.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 464236243263 +8.2%
Inventory Days 19412129965 -78.3%
Days Payable 273310452210 -53.5%
Cash Conversion Cycle 3854790118 +31.1%
Working Capital Days -566-656105138 +31.4%
ROCE % 6%3%2%4% +100.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 45.78%45.80%45.81%45.82%45.82%45.82% +0.0%
FIIs 3.66%4.28%3.35%3.64%6.62%6.01% -9.2%
DIIs 9.51%8.62%9.32%9.62%9.77%10.84% +11.0%
Public 41.03%41.30%41.54%40.92%37.79%37.33% -1.2%
No. of Shareholders 36,38934,91734,40134,12636,49842,642 +16.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Senores Pharmaceuticals Limited's revenue in Q1 FY27?
Senores Pharmaceuticals Limited reported revenue of ₹27 crore for the quarter ended June 2026 (Q1 FY27), up 36.2% from ₹20 crore in the same quarter last year, and down 26.7% sequentially over the March 2026 quarter.
What was Senores Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit fell 61.9% year-on-year to ₹1 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.22.
What is SENORES's market capitalisation and P/E ratio?
At the current price of ₹1,318.40, SENORES has a market capitalisation of ₹6,072 crore and a trailing P/E of about 326.6.
Who owns Senores Pharmaceuticals Limited? (shareholding pattern)
As of Sep 2026, promoters held 45.82%, foreign institutional investors (FIIs) 6.01%, domestic institutional investors (DIIs) 10.84%, public shareholders 37.33% of Senores Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI